SquareMind raises $18M for AI-powered skin imaging robot

Paris-based SquareMind raised $18 million to commercialize its Swan robot, which uses artificial intelligence and robotics for full-body dermoscopic skin imaging. The funding includes previously undisclosed pre-Series A financing. Sonder Capital led the round, with participation from the French government's Deeptech 2030 Fund, Adamed Technology, Calm/Storm Ventures, Teampact Ventures, and several prominent entrepreneurs. SquareMind plans to use the capital to grow its commercial, engineering, and customer support teams ahead of a near-term commercial launch in the U.S. and Europe. The Swan robot is designed to capture standardized, full-body dermoscopic skin images while guiding patients with visual and audio prompts for a short, contactless exam completed in minutes. The company said the technology acts as an augmented dermatoscope, providing a view of the entire skin surface at a level typically obtained when examining moles up close. Image acquisition is automated and integrates into clinical workflows. The system pairs with AI-based software to help track new or changing moles over time, while physicians retain full clinical judgment. SquareMind co-founder and CEO Ali Khachlouf said the technology is already seeing strong traction from hospitals and dermatology practices. He noted that dermatologists face increasing pressure and cognitive load, and that the technology helps reduce this burden while supporting comprehensive documentation. The company highlighted that skin screening is the highest-volume procedure in dermatology, with demand outpacing capacity due to an aging population concerned with skin care. Time constraints leave little room for thorough documentation, which is important for early detection because 80 percent of melanomas are new lesions. The Swan robot has a CE mark and is FDA 510(k) exempt as a Class I device. Commercialization is expected to begin sometime in 2026.